Fig. 2: Human recombinant chemerin (rh-chemerin) treatment improved short-term neurological deficits and reduced infarct area at 24 h after hypoxic–ischemic encephalopathy (HIE). | Cell Death & Disease

Fig. 2: Human recombinant chemerin (rh-chemerin) treatment improved short-term neurological deficits and reduced infarct area at 24 h after hypoxic–ischemic encephalopathy (HIE).

From: RETRACTED ARTICLE: Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic–ischemic encephalopathy

Fig. 2: Human recombinant chemerin (rh-chemerin) treatment improved short-term neurological deficits and reduced infarct area at 24 h after hypoxic–ischemic encephalopathy (HIE).

a, b Triphenyltetrazolium chloride (TTC) staining showing that medium (9 μg/kg) dose of rh-chemerin treatment significantly reduced infarct area when compared with vehicle, low (3 μg/kg), and high (27 μg/kg) dose of rh-chemerin treatment. c, d Righting reflex (c) and geotaxis reflex (d) showing that medium dose (9 μg/kg) of rh-chemerin significantly improved neurological function compared with vehicle pups. e Vehicle-treated pups showed to lose significant weight compared with sham and all three treatment groups after HIE. Data are mean ± SD. Analysis of variance (ANOVA), Tukey; *p < 0.05 compared with sham, #p < 0.05 compared with HIE+vehicle, @p < 0.05 compared with HIE+rh-chemerin (9 μg/kg), n = 6/group

Back to article page